Navigation Links
Worldwide Clinical Trials Emerges as Leading Global Contract Research Organization
Date:7/9/2008

- Provides expertise in high-growth therapeutic areas to pharmaceutical and

biotechnology companies

- Aggressive acquisition strategy over the last year

BEVERLY HILLS, Calif., July 9 /PRNewswire/ -- Worldwide Clinical Trials, Inc.("WCT"), formed by Dr. Neal R. Cutler and a team of scientists, today reached a milestone in establishing itself as a premier global contract research organization with the announcement that it has closed the acquisition of MediQuest, a contract research organization providing specialized clinical development services to biopharmaceutical companies. The MediQuest acquisition was the most recent of five acquisitions made by WCT over the last year including Evidence Clinical and Pharmaceutical Research LLC, Clinical Studies Management Group, Inc., Nottingham Clinical Research Limited and CEDRA Corporation. The five acquisitions extend WCT's global footprint to more than 30 countries.

WCT is a leading therapeutically focused contract research organization that applies deep therapeutic expertise to help customers achieve their drug development goals. WCT provides clinical consulting and Phase I-IV drug development services -- including clinical trial design, clinical operations, data management, biostatistics, medical affairs, safety/pharmacovigilance, Electronic Data Capture and Interactive Voice Response System technologies, regulatory affairs, quality assurance bioanalytical services (LC-MS-MS, ligand binding, biomarkers), and pharmacokinetics -- for global pharma, specialty pharma and biotech companies.

Formed in 2007 by Dr. Cutler in partnership with The Jordan Company, a leading private equity firm, the company focuses on complex, high-growth therapeutic areas with primary expertise in central nervous system, and cardiovascular disease, along with significant experience in chronic inflammatory disease, metabolic / endocrinology and oncology. As expertise in these areas continues to be in demand, Worldwide Clinical Trials has sought to broaden its business through strategic growth and a highly selective acquisition strategy of companies that complements its existing skill-set.

"The acquisitions we have completed to date significantly enhance our contract research organization capabilities and our ability to manage large, global trials, within our primary therapeutic areas of focus. That in turn positions us well for future growth," said Dr. Cutler. "We have effectively expanded our operations and significantly enhanced our ability to meet the global needs of pharma and biotech companies. Our presence in Eastern Europe and Russia, two of the most attractive growth regions for clinical trials, helps transform our business into a truly global contract research organization."

Dr. Cutler and his team have reunited under the name of their former company, Worldwide Clinical Trials, which they founded in 1994 and sold to UnitedHealth in 1999. Dr. Cutler is known for pioneering several revolutionary techniques that increased the quality, safety and speed of drug development.

About Worldwide Clinical Trials, Inc.

Worldwide Clinical Trials (http://www.wwctrials.com) is a full-service contract research organization (CRO) that is medically and scientifically focused on central nervous system (CNS) and cardiovascular disease. WCT delivers quality clinical trials with leading edge science and medicine to help clients think through design, methodology and regulatory issues that are unique to every development program. WCT provides highly focused CRO services in all phases of research -- worldwide.

About The Jordan Company

The Jordan Company (http://www.thejordancompany.com), founded in 1982, is a leading middle-market private equity firm with over $6 billion of assets under management and a successful track record of investing in and growing businesses across a wide range of industries. The firm's partners have been investing together for more than two decades, establishing The Jordan Company as one of the most experienced and stable investment teams in private equity. The investment team is supported by the firm's Operations Management Group, which initiates and supports operational improvements in portfolio companies. The firm generates deal flow through a well-developed network of sourcing relationships. Headquartered in New York, The Jordan Company also has offices in Chicago and Shanghai.


'/>"/>
SOURCE Worldwide Clinical Trials, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Pfizer and Bristol-Myers Squibb Finalize Agreement for Worldwide Collaboration on Metabolic Disorders Program
2. Avicena Signs Worldwide Exclusive Distribution Agreement with RITA Corporation for its Proprietary Dermaceutical Compounds
3. Stereotaxis Niobe System Used to Perform More Than 10,000 Procedures Worldwide
4. Martek Signs Multi-Year Worldwide Sole Source Supply Agreement with Abbott
5. MultiCell Technologies Signs Worldwide Exclusive License Agreement With Corning Incorporated
6. AstraZeneca Bolsters Its Worldwide Biologics Division Through Integration of Cambridge Antibody Technology Into MedImmune
7. REMICADE(R) Becomes First Anti-TNF Biologic Therapy to Treat One Million Patients Worldwide
8. Co-Inventor of Amgens Aranesp(R) Technology Directs Worldwide Patent Strategy for Diffusion Pharmaceuticals First-in-Class Oxygen Enhancing Therapeutics
9. Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen
10. Novo Nordisk Appoints Alan C. Moses as Chief Medical Officer Worldwide
11. Starion Achieves Worldwide Distribution of Proprietary Tissue Welding Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... YORK , Jan. 18, 2017 ... to reach USD 92.9 billion by 2025, according ... Inc. Pharmaceutical industry has been adaptive of the ... as early as 2002. Among the services outsourced, ... forerunners. For instance, Johnson & Johnson was the ...
(Date:1/19/2017)... , Jan. 18, 2017 Acupath Laboratories, Inc., ... the formation of an Executive Committee that will guide ... John Cucci , a 15-year veteran ... Director of Business Development to Chief Sales Officer ... Cucci served in senior sales leadership roles at several ...
(Date:1/18/2017)... ... January 18, 2017 , ... ... interconnect using USB or PCI Express, announced the ZEM5310 USB 3.0 FPGA Module, ... into a compact business-card sized form factor suitable for prototyping, testing, and production-ready ...
(Date:1/18/2017)... --  Boston Biomedical , an industry leader in the ... pathways, will feature data from two clinical studies for ... Gastrointestinal Cancers Symposium, held from January 19-21, in ... is an orally-administered investigational agent designed to inhibit cancer ... cells (CSCs) possess the property of stemness – the ...
Breaking Biology Technology:
(Date:12/20/2016)... 20, 2016 The rising popularity of ... leasing is stoking significant interest in keyless access ... Bluetooth low energy (BLE), biometrics and near-field communication ... wave of wireless technologies in the automotive industry. ... advanced access systems opens the market to specialist ...
(Date:12/16/2016)... DUBLIN , Dec 16, 2016 Research ... Access System Market - Global Forecast to 2021" report to ... ... projected to grow at a CAGR of 14.06% from 2016 to ... 2016, and is projected to reach 854.8 Million by 2021. The ...
(Date:12/15/2016)... ... and Markets has announced the addition of the "Global Military Biometrics ... forecasts the global military biometrics market to grow at a CAGR of ... prepared based on an in-depth market analysis with inputs from industry experts. ... coming years. The report also includes a discussion of the key vendors ...
Breaking Biology News(10 mins):